On October 1, 2025 Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel approaches to tissue protection in oncology-related radiation exposure and mitigating the inflammatory response in pulmonary disease, reported that the Company will be hosting a virtual panel on October 08, 2025, 1:30 pm EDT, entitled "Mitigating Tissue Damage in Radiation Oncology and Inflammation in Pulmonary Disease: Targeting Pathways of Tissue Injury and Inflammatory Response (Press release, Humanetics, OCT 1, 2025, View Source [SID1234656386])."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Panel members include:
Rany Condos, MD, Director, Interstitial Lung Disease Program and Post-COVID Program, NYU Langone
Pranshu Mohindra, MD, MMM, Professor and Vice Chair of Operations and Quality for the Department of Radiation Oncology and Director of the University Hospitals Proton Therapy Center, University Hospitals Cleveland Medical Center
Colin G. Chinn, MD, MHS, FACP, RADM MC USN (Ret), Chief Medical Officer, Humanetics
Michael D. Kaytor, PhD, Vice President, Research & Development, Humanetics
Hannah Olson, PhD, Research & Development Scientist, Humanetics
This panel will explore advances in addressing unmet medical needs related to oncology and radiation exposure, as well as pulmonary disease and inflammation. Leading oncology and pulmonary medicine clinicians, together with researchers, will share perspectives on emerging data, trial design, clinical practice challenges, and insights into potential therapeutic targets.
A live Q&A session will follow the panel discussion.
Humanetics convened an expert panel on August 12, 2025, that explored its Medical Countermeasure development program. As discussed, protecting Warfighters from tissue damage due to accidental or intentional ionizing radiation exposure remains a priority for the United States as well as its allies and partners. Likewise, safeguarding emergency medical personnel, first responders, and civilian populations is among the domestic imperatives for Strategic National Stockpile decision makers. Access to the video recording of the August 12 session is available on the Humanetics Corporation website under "News & Events."